Talk:Michael A. Santoro
This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE. |
Edit request
[edit]This edit request by an editor with a conflict of interest has now been answered. |
Issue: Notability tag requiring secondary sources.
Update suggested: The following secondary sources be incorporated into the article.
Edit request
|
---|
A) Section: "Fair Share" Theory of Business Responsibility for Human Rights
[edited to add |quote= parameter]
B) Section: Wall Street ethics and the financial crisis
[5][edited to add |quote= parameter]
In 2013, a study by Labaton Sucharow, a New York City law firm, found that in a survey of 250 financial professionals, 29% said “they believed financial services professionals may need to engage in unethical or illegal activity in order to be successful.” Santoro stated “no amount of structural reform and government regulation will ensure the stability of the global financial system unless the ethical practices and values of Wall Street professionals are aligned with market efficiency and the public welfare.”
C) Section: Pharmaceutical Industry Ethics
[6][edited to add |quote= parameter]
|
VAU2020 (talk) 22:12, 18 December 2019 (UTC) ; edited 18:37, 21 January 2020 (UTC)
References
- ^ Koehn, D (2003). "Spotting Ethical Spin-Offs: A Review of Michael Santoro's "Profits and Principles"". Business Ethics Quarterly. 12 (2): 257-260.
Santoro distinguishes between two types of Western companies with operations in China.
- ^ Koehn, D (2003). "Spotting Ethical Spin-Offs: A Review of Michael Santoro's "Profits and Principles"". Business Ethics Quarterly. 12 (2): 257-260.
Santoro found that the presence of companies of the first type has generally been positive. Santoro offers what he calls a 'Theory of Human Rights Spin-Off.'
- ^ Koehn, D (2003). "Spotting Ethical Spin-Offs: A Review of Michael Santoro's "Profits and Principles"". Business Ethics Quarterly. 12 (2): 257-260.
While conceding the need to be skeptical, Santoro insists that there is a positive spin-off.
- ^ Koehn, D (2003). "Spotting Ethical Spin-Offs: A Review of Michael Santoro's "Profits and Principles"". Business Ethics Quarterly. 12 (2): 257-260.
Whether or not these spin-offs take hold will depend, I believe, on the extent to which they are reinforced by deeply held Chinese cultural values.
- ^ McCoy, Kevin. "Survey questions Wall Street ethics". USA Today. USA Today. Retrieved 19 December 2019.
The survey results found a similar decline in ethics as the one highlighted in Wall Street Values, a recently published book by two business academics in New Jersey. Michael Santoro, a professor at Rutgers University Business School, and Ronald Strauss, an assistant professor at Montclair State University School of Business, concluded that "no amount of structural reform and government regulation will ensure the stability of the global financial system unless the ethical practices and values of Wall Street professionals are aligned with market efficiency and the public welfare."
- ^ Sandberg, Joakim (2010). "Ethics and the Pharmaceutical Industry: Book Review". European Journal of Health Law (17): 212. Retrieved 19 December 2019.
With notable acumen, however, Santoro's introductions give a both philosophically and empirically insightful overview of the many interesting ethical and political issues which the practices of the pharmaceutical industry give rise to — and these introductions often go well beyond the contents of the papers which succeed them. At the core of most ethical and political debates in this area, Santoro suggests, lies the issue of profit versus people, or the conflict between the profit-maximising nature of companies and the medical needs of the public. The challenge is to find a reasonable balance between these two, and this challenge permeates issues like what the research activities of pharmaceuticals should be, fairness in allocation of pharmaceutical benefits, and what an ethically legitimate patent regime could look like.
Reply 18-DEC-2019 (I)
[edit]Reply from Spintendo (I)
|
---|
Notes
|
Regards, Spintendo 05:35, 19 December 2019 (UTC)
Reply 21-JAN-2020 (II)
[edit]- Thank you for using the guidelines at WP:REDACTED, it is much appreciated.
- Unfortunately however, a single portion of your edit request still cannot be reviewed because the claims made do not contain clearly placed ref tags. When proposing edit requests, it is important to highlight in the text, through the use of ref tags, which specific sources are doing the referencing for each claim. The point of these ref tags is to allow the reviewer and readers to check that the material is sourced; that point will be lost if the references are not clearly placed. In the collapsed section below titled Request edit examples, I have illustrated two: The first shows how the edit request was submitted; the second shows how requests should be submitted in the future.
Request edit examples
|
---|
In the example above there are three references provided for the stated claims. But these ref tags have been bundled at the end of the text, and because of this, the tags do not indicate which reference applies to which claim. In one portion of your edit request the ref tags are similarly bundled. The links between these claims and their source references must be clearly made, as shown in the next example below:
In the example above the links between the provided references and each claim statement is perfectly clear. Because each reference speaks to a particular part of the text, the ref tags need to be clearly placed. |
- Kindly reformulate your edit request so that it aligns more with the second example above, and feel free to re-submit as a new edit request below this post at your earliest convenience. Regards, Spintendo 06:19, 22 January 2020 (UTC)
Request for addition of secondary sources
[edit]This edit request by an editor with a conflict of interest was declined. Please see the reply section below for additional information about this request. |
This is a request to add secondary sources to the text (per the notability tag requiring more secondary sources).
The first two are suggestions of new text to add with a corresponding secondary source. The third suggestion is to add a secondary source as a reference to existing text.
Suggestion 1: Add additional sentence in section "Fair Share" Theory of Business Responsibility for Human Rights. Could be inserted as second sentence in the first paragraph. New suggested text (this is not a quote from the source):
The book lays out two types of Western companies operating in China and proposes “A Theory of Human Rights Spin-Off.”[1]
Suggestion 2: Add additional sentences in section Wall Street ethics and the financial crisis. Could be added to paragraph one. New suggested text:
Santoro and Strauss conclude that "no amount of structural reform and government regulation will ensure the stability of the global financial system unless the ethical practices and values of Wall Street professionals are aligned with market efficiency and the public welfare."[2]
Suggestion 3: Add this reference to the section Pharmaceutical Industry Ethics. The following sentence is currently the second sentence of the first paragraph:
In an introductory chapter, Santoro describes "the unravelling of the "grand bargain" between the pharmaceutical industry and society.[3]
VAU2020 (talk) 01:30, 6 February 2020 (UTC)
References
- ^ Koehn, D. (2003). "Spotting Ethical Spin-Offs: A Review of Michael Santoro's "Profits and Principles"". Business Ethics Quarterly. 12 (2): 257–260. Retrieved February 5, 2020.
- ^ McCoy, Kevin (July 16, 2013). "Survey questions Wall Street ethics". USA Today. Retrieved February 5, 2020.
- ^ Sandberg, J. (2010). "Ethics and the Pharmaceutical Industry: Book Review". European Journal of Health Law (17): 212. Retrieved February 5, 2020.
Reply 5-FEB-2020
[edit]Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Spintendo 02:45, 6 February 2020 (UTC)
Proposal review 5-FEB-2020
|
---|
|
Request to add new content/secondary source
[edit]This edit request by an editor with a conflict of interest has now been answered. |
This is a request to add a secondary source to the text (per the notability tag requiring more secondary sources).
Suggestion: Add additional content in section "Fair Share" Theory of Business Responsibility for Human Rights. New suggested text is below (note that if the quoted section of the review is too long, perhaps just the first sentence ending "...deeply held Chinese cultural values" would be sufficient to add the jist of the reviewer's analysis). This could be added after the first sentence of the section; or, alternatively, as new paragraphs below the existing content:
Santoro proposes a “Theory of Human Rights Spin-off” where Western companies operating in China may have a positive impact on human rights as a natural outcome of their day-to-day operations.[1]
Reviewer Daryl Koehn wrote that “Santoro’s argument is persuasive because he documents these spin-offs in detail”; however, Koehn argues that “Whether or not these spin-offs take hold will depend, I believe, on the extent to which they are reinforced by deeply held Chinese cultural values. For example, the Confucian stress on the inward turn - the need to critically assess one’s own performance before criticizing other people - would seem to reinforce a duties-based perspective rather than a human rights ethic. These values can and do evolve, but the evolution is typically subtle. New values modify old ones, rather than replacing them wholesale.”[2]
VAU2020 (talk) 23:44, 5 March 2020 (UTC)
References
- ^ Santoro, Michael A. (2000). Profits and Principles: Global Capitalism and Human Rights in China. Cornell University Press. ISBN 0801435013.
- ^ Koehn, D. (2003). "Spotting Ethical Spin-Offs: A Review of Michael Santoro's "Profits and Principles"". Business Ethics Quarterly. 12 (2): 257–260. Retrieved February 5, 2020.
- Thank you for improving the edit request, it is much appreciated. With regards to the description of the book as one where the author states that MNC's "operating in China may have a positive impact on human rights as a natural outcome of their day-to-day operations", the claim does not state how and in what way the MNC's would have this impact. This is important here because the next requested section has the author Koehn stating that Santoro's argument is persuasive. But we're not given the details of that argument. Those include:
- the variables which have an "elective affinity" with human rights
- the argument that MNC's create a "new meritocracy"
- the redefinition of power relationships in China
- the emphasis on information sharing and teamwork
- It is, of course, inevitable that the section here would be unable to go into much detail about the book, since that is not the main topic. That information would be germane for an article on the book. In any event, if the book is to be mentioned here, it needs to be more specific with regards to what it is describing (i.e., the author's main claims mentioned above, and the review of those claims - specifically which part of Santoro's argument Koehn meant when he stated "Santoro's argument is persuasive"). Additionally, the pages cited for Koehn need to be page 259 and page 260, not 257 through 260. The page(s) for Santoro should also be given. Regards, Spintendo 20:54, 19 March 2020 (UTC)
- Biography articles of living people
- Unassessed biography articles
- Unassessed biography (science and academia) articles
- Unknown-importance biography (science and academia) articles
- Science and academia work group articles
- WikiProject Biography articles
- Talk pages of subject pages with paid contributions
- Implemented requested edits
- Declined requested edits